Antrafenine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317196

CAS#: 55300-30-6 (HCl)

Description: Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.

Chemical Structure

Antrafenine HCl
CAS# 55300-30-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 317196
Name: Antrafenine HCl
CAS#: 55300-30-6 (HCl)
Chemical Formula: C30H28Cl2F6N4O2
Exact Mass: 588.196
Molecular Weight: 661.4704
Elemental Analysis: C, 54.47; H, 4.27; Cl, 10.72; F, 17.23; N, 8.47; O, 4.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 55300-29-3 (free base)   55300-30-6 (HCl)    

Synonym: Antrafenine HCl, SL 73-033, SL-73-033; SL73-033; SL 73033, SL-73033; SL73033; Stakan, Stakane; Antrafenine hydrochloride

IUPAC/Chemical Name: 2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate dihydrochloride


InChi Code: InChI=1S/C30H26F6N4O2.2ClH/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27;;/h1-11,18-19H,12-17H2,(H,37,38);2*1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 661.4704 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wang Y, Law WK, Hu JS, Lin HQ, Ip TM, Wan DC. Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening. J Chem Inf Model. 2014 Nov 24;54(11):3046-50. doi: 10.1021/ci500503b. Epub 2014 Nov 4. PubMed PMID: 25360897.

2: Normand M, Bergua D, Bouvet JP, Cayotte JL, Gottis M. [Correlation of the cause and composition of renal calculi. Value of morphologic and infrared analysis]. Ann Biol Clin (Paris). 1989;47(1):29-34. Review. French. PubMed PMID: 2648901.

3: Moesch C, Rince M, Raby C, Leroux-Robert C. [Identification of a metabolite of floctafenine in urinary calculi]. Ann Biol Clin (Paris). 1987;45(5):546-50. French. PubMed PMID: 2892454.

4: Daudon M, Moesch C, Marty L, Normand M, Rince M, Leroux-Robert C, Reveillaud RJ. [Antrafenine, urinary calculi and crystalluria]. Therapie. 1986 Nov-Dec;41(6):499-504. French. PubMed PMID: 3810546.

5: Cheymol G, Biour M, Bruneel M, Albengres E, Hamel JD. [Evaluation of a national prospective survey on the undesirable effects of glafenine, antrafenine and floctafenine]. Therapie. 1985 Jan-Feb;40(1):45-50. French. PubMed PMID: 2860731.

6: Caccia S, Conti I, Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. J Pharm Pharmacol. 1985 Jan;37(1):75-7. PubMed PMID: 2858538.

7: Hensby CN, Maloubier A, Civier A, Shroot B, Ortonne JP. A model for studying the anti-prostaglandin activity of drugs in human skin. Br J Dermatol. 1984 Jul;111 Suppl 27:147-51. PubMed PMID: 6743546.

8: Dunn CJ, Prouteau M, Delahaye M, Purcell T, Branceni D. Antrafenine: anti-inflammatory activity with respect to oedema and leucocyte infiltration in the rat. Agents Actions. 1984 Feb;14(2):296-9. PubMed PMID: 6608864.

9: Caccia S, Notarnicola A, Fong MH, Benfenati E. Identification and quantitation of 1-arylpiperazines, metabolites resulting from side-chain cleavage of (4-substituted aryl-1-piperazinyl)alkyl heterocyclic derivatives in rat plasma and brain. J Chromatogr. 1984 Jan 20;283:211-21. PubMed PMID: 6707118.

10: Nicot G, Merle L, Coquelin JP, Valette JP, Lachatre G. [Proteins and urinary enzymes following administration of antrafenine in healthy volunteers]. Therapie. 1983 Jul-Aug;38(4):379-86. French. PubMed PMID: 6648882.